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Strengths and limitations of this study
 ► The HEMICU (Diagnostic biomarkers for adult hae-
mophagocytic lymphohistiocytosis in critically ill 
patients) study is the first prospective study to in-
vestigate biomarkers for the diagnosis of adult hae-
mophagocytic lymphohistiocytosis (HLH) in intensive 
care unit (ICU) patients.
 ► The variety of analysed biomarkers will provide a 
better understanding of adult HLH pathophysiology.
 ► Biobanking of DNA, plasma and serum of adult HLH 
patients will generate a database to investigate fu-
ture research questions.
 ► This study might be limited in that it only includes 
ICU patients and findings will not be generalisable to 
non- ICU patients.
AbStrACt
Introduction Haemophagocytic lymphohistiocytosis (HLH) 
in adults is characterised by toxic immune activation 
and a sepsis- like syndrome, leading to high numbers of 
undiagnosed cases and mortality rates of up to 68%. Early 
diagnosis and specific immune suppressive treatment 
are mandatory to avoid fatal outcome, but the diagnostic 
criteria (HLH-2004) are adopted from paediatric HLH and 
have not been validated in adults. Experimental studies 
suggest biomarkers to sufficiently diagnose HLH. However, 
biomarkers for the diagnosis of adult HLH have not yet 
been investigated.
Methods and analysis The HEMICU (Diagnostic 
biomarkers for adult haemophagocytic lymphohistiocytosis 
in critically ill patients) study aims to estimate the 
incidence rate of adult HLH among suspected adult 
patients in intensive care units (ICUs). Screening 
for HLH will be performed in 16 ICUs of Charité – 
Universitätsmedizin Berlin. The inclusion criteria are 
bicytopaenia, hyperferritinaemia (≥500 µg/L), fever or when 
HLH is suspected by the clinician. Over a period of 2 years, 
we expect inclusion of about 100 patients with suspected 
HLH. HLH will be diagnosed if at least five of the HLH-2004 
criteria are fulfilled, together with an expert review; all 
other included patients will serve as controls. Second, a 
panel of potential biomarker candidates will be explored. 
DNA, plasma and serum will be stored in a biobank. The 
primary endpoint of the study is the incidence rate of 
adult HLH among suspected adult patients during ICU 
stay. Out of a variety of measured biomarkers, this study 
furthermore aims to find highly potential biomarkers 
for the diagnosis of adult HLH in ICU. The results of this 
study will contribute to improved recognition and patient 
outcome of adult HLH in clinical routine.
Ethics and dissemination The institutional ethics 
committee approved this study on 1 August 2018 (Ethics 
Committee of Charité – Universitätsmedizin Berlin, 
EA4/006/18). The results of the study will be disseminated 
in an international peer- reviewed journal and presented at 
international conferences.
trial registration number NCT03510650.
IntroduCtIon
Haemophagocytic lymphohistiocytosis 
(HLH) is a hyperinflammatory syndrome 
that is due to toxic immune activation and 
is associated with multiple organ failure and 
high mortality in intensive care unit (ICU) 
patients.1–3 Primary HLH due to genetic 
causes has been the subject of extensive 
research in paediatric medicine, resulting in 
an advanced understanding of its pathophys-
iology including identification of underlying 
genetic defects related to cytotoxic granule 
exocytosis.4 However, much less is known 
about HLH in adults, where the secondary 
form triggered by infections, autoimmune 
diseases, malignancies or immunosuppres-
sive therapy is more common. Both heredi-
tary primary and reactive secondary HLH are 
characterised by impaired immune function, 
that is, impaired natural killer (NK) or cyto-
toxic T cell function leading to abnormal 
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box 1 HLH-2004 diagnostic criteria6
HLH-2004 diagnostic criteria of which at least five must be fulfilled.
 ► Ferritin ≥500 µg/L.
 ► Fever (≥38.2°C).
 ► Splenomegaly.
 ► Cytopaenias in ≥2 lines (haemoglobin <90 g/L, platelets <100×109/L, 
neutrophils <1.0×109/L).
 ► Hypertriglyceridaemia and/or hypofibrinogenaemia (fasting tri-
glycerides ≥2.65 g/L, fibrinogen <1.5 g/L).
 ► Haemophagocytosis in bone marrow or spleen or lymph nodes.
 ► Low or absent natural killer cell activity.
 ► Soluble CD25 (soluble interleukin-2 receptor) ≥2400 U/mL.
HLH, haemophagocytic lymphohistiocytosis. Figure 1 Screening protocol and blood sampling. HLH, 
haemophagocytic lymphohistiocytosis; ICU, intensive care 
unit.
activation of cytokine- releasing macrophages and T cells, 
and finally to an uncontrolled inflammatory condition 
known as cytokine storm.5
Currently, diagnosis is based on the HLH-2004 criteria 
(box 1) derived from the paediatric HLH-2004 protocol, 
which has not been validated in adult patients with 
HLH.6 7 Moreover, diagnosis of HLH in ICU- admitted 
patients is hampered by its sepsis- like presentation. 
Clinical features include repetitive fever, hepatomegaly 
and/or splenomegaly and antibiotic- refractory infec-
tions, as well as pulmonary and renal involvement with 
consequent multiple organ failure.7 Laboratory findings 
may reveal cytopaenia, hypertriglyceridaemia, hyper-
ferritinaemia and hypofibrinogenaemia. Timely diag-
nosis is crucial to initiate adequate treatment and thus 
to improve prognosis. As demonstrated by Jordan et al,8 
early therapy reduces mortality to 30%–35%. However, 
up to 78% of all HLH cases in ICU remain undiagnosed, 
leading to mortality rates as high as 68%.2 9 Given the 
lack of specific diagnostic tests and the established use of 
unvalidated diagnostic criteria in adults, we aim to iden-
tify a biomarker panel of high sensitivity and specificity to 
allow early detection of HLH in critically ill patients.
MEtHodS And AnALySIS
design and screening
Over a 2- year period (ongoing since 1 September 2018), 
screening of all patients admitted to 16 adult ICUs of 
Charité – Universitätsmedizin Berlin will be performed. 
As part of the process, electronic patient charts will be 
screened daily for bicytopaenia by an automated script. 
All patients with bicytopaenia are searched daily by the 
study team for HLH-2004 criteria (box 1), HScore10 and 
suspected HLH by clinicians. If highly suspected of HLH, 
the patient will be enrolled after informed consent by 
the patient himself or a legal representative. Immediately 
after study enrolment and before initiation of specific 
HLH treatment, whole blood samples will be obtained 
for all analyses. Additionally, plasma and serum samples 
as well as DNA will be stored in a biobank (figure 1). HLH 
will be diagnosed if at least five of the HLH-2004 criteria 
are fulfilled and finally confirmed after a case- by- case 
review by two HLH experts. The study aims to include at 
least 100 patients with suspected HLH. Patients in whom 
HLH is not confirmed will serve as controls.
Study population and eligibility criteria for patients
Inclusion criteria
 ► ICU patients of at least 18 years old.
 ► Suspected or diagnosed HLH: based on the HLH-2004 
diagnostic criteria (bicytopaenia, hyperferritinaemia 
(≥500 µg/L), fever) or as suspected by clinicians.
 ► Eligible to informed consent by the patient himself or 
a legal representative.
Exclusion criteria
 ► Participation in an interventional study.
 ► Female patients who are pregnant or breast feeding.
Setting
Participating ICUs include anaesthesiological, surgical, 
medical, neurological and mixed ICUs. In total, 16 ICUs 
of Charité – Universitätsmedizin Berlin will provide 
patients.
objectives and hypotheses
This study aims to investigate critically ill patients for adult 
HLH and estimate its incidence rate among suspected 
patients during ICU stay. Second, a panel of various 
biomarker candidates from experimental and paediatric 
studies will be measured to explore potential to diag-
nose HLH in adult ICU- admitted patients. As a result, 
HLH might be detected earlier, leading to an improved 
outcome. Highly sensitive biomarkers may also help to 
distinguish HLH from sepsis.
Patient and public involvement
Patients or the public were not involved in the develop-
ment of the research question, design, recruitment and 
conduct of this study. The results of immunological anal-
yses will be sent immediately to the physicians in charge. 
Patients will be informed of the global results of the study 
at their request.
M
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Statistical analyses
The incidence rate of HLH among suspected adult 
patients during ICU stay will be calculated with 95% 
CI. Investigation of potential biomarkers will be explor-
atory. Descriptive statistics between patient groups with 
confirmed HLH and controls will incorporate mean 
and SD or absolute and relative frequencies depending 
on each variable’s scale. Univariable and multivariable 
logistic regression models with confirmed HLH diagnosis 
as outcome will be calculated for different combinations 
of influencing variables and biomarkers. Receiver oper-
ating characteristic analysis will be performed to deter-
mine discrimination ability as measured by the area under 
the curve for each continuous biomarker. Sensitivity and 
specificity within our patient sample will be given for cut- 
off points with the highest Youden index. Highly poten-




 ► Incidence rate of adult HLH among suspected 
patients during ICU stay.
Secondary endpoints
 ► Identification of highly sensitive and highly specific 
biomarkers to safely diagnose adult HLH in ICU.
 ► Trigger and underlying conditions.
 ► Therapy of HLH by clinicians.
 ► ICU and hospital length of stay.
 ► Mortality and survival after 6 months.
 ► Quality of life questionnaire '36- item Short Form 
Health Survey' after 6 months.11
 ► HIV antibodies and antigen.
 ► Epstein- Barr virus and cytomegalovirus viral loads.
 ► Inflammatory markers (ferritin, C reactive protein, 
procalcitonin, interleukin (IL)-1β, IL-2, IL-6, IL-8, 
IL-10, IL-18, IL-33, tumour necrosis factor (TNF)-α, 
interferon (IFN)-ɣ, sCD25, sCD163 and presepsin).12
 ► Perforin and CD107a.13
 ► Fibrinogen, triglycerides, bilirubin, lactate dehydro-
genase, alanine aminotransferase (ALAT) and aspar-
tate aminotransferase (ASAT).
 ► Sodium, serum albumin and serum protein 
electrophoresis.
 ► Detailed immune status (differential blood count, 
T cells (CD3+), B cells (CD19+), NK cells (CD16+), 
T helper cells (CD4+), cytotoxic T cells (CD8+), 
CD4:CD8 ratio, human leucocyte antigen (HLA)- DR 
of CD8+, CD11a of CD8−, CD57 of CD8−, CD28 of 
CD8+, HLA- DR of monocytes, CD56bright and CD69 
of NK cells).
 ► Glycosylated ferritin14 and microRNAs (miR-205- 5p, 
miR-194- 5p and miR- 30c- 5p).15
 ► Chemokines CCL2 (MCP-1), CCL3, CCL4, CCL5 
(RANTES), CCL11 (eotaxin), CCL19, CCL20, 
CXCL1, CXCL9, CXCL8 (IL-8), CXCL10 (IP-10) and 
CXCL12 (SDF1A).16
 ► HLA typing.
 ► Biobanking for future research questions (eg, genetic 
polymorphisms and gene expression of PRF1, 
UNC13D, STX11 and STXBP27).
data collection
The number of screened patients, the number of patients 
with suspected HLH who could not be included as well as 
data on all outcome measures will be collected prospec-
tively. If the patient received immunosuppressive therapy 
prior to inclusion, this will be documented separately. 
Further data including patient demographic data, past 
medical conditions, physicians’ reports and routine 
laboratory results will be abstracted from the hospital’s 
database. For follow- up 6 months after study inclusion, 
patients will be contacted either by telephone or by mail 
as indicated on enrolment to assess health- related quality 
of life and mortality, respectively.
Immunological measurements
Plasma concentrations of soluble IL- 2R (sIL- 2R or sCD25) 
will be determined with the IMMULITE semiautomatic 
chemiluminescent immunoassay (Siemens Healthcare, 
Erlangen, Germany). Additional soluble factors IL-1β, 
IL-2, IL-6, IL-8, IL-10, IL-18, IL-33, TNF-α and IFN-ɣ will 
be measured by Meso Scale Discovery (Meso Scale Diag-
nostics, Maryland USA). The kit provides all reagents, 
together with a 96- well plate with specific precoated 
spots, the detection antibodies and assay diluent. The 
standard will be reconstituted with assay diluent to obtain 
a lot- specific concentration which differs for all cyto-
kines. The vials are inverted multiple times for mixing, 
and after vortexing the vials will be kept for 5–10 min 
at room temperature (RT) and then on ice until use. 
Preparation of further serial 1:5 dilution of cytokine stan-
dard is performed. Quality controls (low and high) are 
components of the kits, and respective quality control 
ranges are provided by the manufacturer. The quality 
controls (low and high) will be reconstituted with 250 µL 
of deionised water. The vials are inverted multiple times 
for mixing, and after vortexing kept for 5–10 min at 
RT and then on ice until use. Plasma concentrations of 
soluble CD163 protein levels will be determined with the 
Quantikine ELISA Human CD163 Immunoassay (R&D 
Systems, Minneapolis, USA). The minimum detectable 
dose ranged from 0.058 to 0.613 ng/mL. For measure-
ment of presepsin, Presepsin (Human) ELISA Kit will be 
used (BioVision, California, USA) with a detection range 
of 0.156–10 ng/mL.
Flow cytometric analysis of human lymphocyte subsets 
in EDTA whole blood will be performed, as described 
recently.17 Briefly, the following mouse antihuman fluo-
rescently labelled monoclonal antibodies (mAb) are 
used for quantification of lymphocytes subsets and 
analysis of T and NK cell activation markers: cluster of 
differentiation (CD)3 Allophycocyanin- Alexa Fluor 750 
(APC- A750), CD4 energy coupled dye, CD8 APC, CD11a 
fluorescein isothiocyanate (FITC), CD14 FITC, CD16 
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phycoerythrin (PE), CD19 PE- Cy5.5, CD28 PC5, CD45 
Krome- Orange, CD56 PE or CD56 APC, CD57 Pacific 
Blue, CD69 PE, and HLA- DR PE (all from Beckman 
Coulter, Krefeld, Germany). Functional analysis of NK 
cells will be performed using the CD107a degranulation 
assay according to a protocol published by Bryceson et al.18 
Briefly, peripheral blood mononuclear cells (PBMCs) will 
be isolated by density gradient centrifugation and incu-
bated overnight in the presence or absence of 3600 IU/
mL recombinant IL-2 (Peprotech). PBMC will then be 
incubated with the target cell line K562 (ATCC) in a 
1:1 ratio for 3 hours. Subsequently, CD107a expression 
on NK cells is assessed by staining samples with fluores-
cently labelled antibodies against lineage markers and an 
anti- CD107a FITC- labelled mAb (eBioscience). Perforin 
expression in NK cells will be assessed by intracellular 
staining in unstimulated NK cells using the PerFix- nc 
reagent (Beckman Coulter) for cell permeabilisation 
and an APC- labelled antiperforin mAb (eBioscience) 
according to the manufacturer’s instructions.
Expression of HLA- DR on monocytes will be deter-
mined by flow cytometry using a highly standardised 
quantitative assay, as described earlier.19 In short, whole 
blood in Vacutainer tubes (BD Biosciences, San Jose, 
California, USA) containing EDTA is stained with 20 µL 
of monoclonal PE- conjugated anti- HLA- DR and PerCP- 
Cy5.5- conjugated anti- CD14 antibodies (QuantiBRITE 
HLA- DR/monocyte; BD Biosciences) in the dark at 
room temperature for 30 min. Erythrocyte lysis will be 
done with 0.5 mL of lysing solution (BD Biosciences) for 
another 30 min at room temperature. Finally, the cells 
are washed with 1 mL phosphate buffer saline (PBS) 
buffer containing 2% fetal calf serum (FCS) and anal-
ysed on a Navios flow cytometer (Beckman Coulter). 
HLA- DR surface expression on monocytes will be calcu-
lated as mAb bound per cell using the QuantiBRITE PE 
calibration beads. All flow cytometric analyses will be 
performed on a 10- colour Navios flow cytometer using 
the Navios Software (Beckman Coulter). Human glyco-
sylated ferritin will be determined by ELISA (MyBio-
Source, San Diego, USA). The sensitivity of this kit is 
2.0 ng/mL.
The expression of miR-205- 5p, miR-194- 5p and miR- 
30c- 5p will be determined in whole blood, plasma and 
serum using a protocol published by Balcells et al.20 Briefly, 
after RNA isolation, miRNAs are polyadenylated and then 
reverse- transcribed with a special primer (RT- primer). For 
quantitative real- time PCR (qPCR), two specific primers 
for each miRNA are designed using a software tool from 
Busk.21 All primers are tested for specificity and efficiency. 
qPCR will be performed with SYBR Green using Quant-
Studio5 (Thermo Fisher, Darmstadt, Germany). The 
quantification of chemokines involved in cell trafficking 
and effector functions of lymphocytes, granulocytes and 
mononuclear cells from the CC subfamily (CCL2, CCL3, 
CCL4, CCL5, CCL11, CCL19 and CCL20) as well as the 
CXC subfamily (CXCL1, CXCL8 (IL-8), CXCL10 and 
CXCL12) will be performed with the LUNARIS Human 
11- Plex Chemokine Kit (AYOXXA Biosystems, Cologne, 
Germany).
Determination of HLA typing will be performed by 
reverse sequence- specific oligonucleotide assay LABType 
(One Lambda, Canoga Park, California, USA). Typing will 
be assessed on an intermediate resolution level for HLA- A, 
HLA- B, HLA- C, HLA- DRB1, HLA- DQA1 and HLA- DQB1. 
The assay will be performed according to the manufactur-
er’s instructions, and data will be acquired on a Luminex 
FlexMAP 3D machine (Luminex, Austin, Texas, USA).
Informed consent in critically ill patients
Written informed consent will be obtained from all 
patients or their legally authorised representatives. 
Consent for genetic analyses in future projects will be 
obtained separately.
Sample size
The true incidence of adult HLH in ICU is unknown. 
According to our own research9 and the annual number of 
patients admitted to our ICU, we expect to see about 200 
patients with diagnosed HLH over 2 years and about 400 
with suspected HLH. Of these, we hope to include at least 
100 patients with suspected HLH into the study, of whom 
about 50 patients are expected to be diagnosed with HLH. 
When the sample size is 100, a two- sided 95.0% CI for a 
single proportion using the large sample normal approxi-
mation will extend 0.1 from the observed proportion for an 
expected proportion of 0.5 (nQuery Advisor V.7.0).
dissemination
The study was registered with  ClinicalTrials. gov on 27 April 
2018. The results of the study will be disseminated in an 
international peer- reviewed journal and presented at inter-
national conferences.
dISCuSSIon
HLH is a rare condition in adults with poor prognosis. 
Due to the paucity of data available on adult HLH, 
recognition remains low, resulting in delayed diagnosis 
and treatment, and finally fatal outcome. This is the first 
prospective study to systematically investigate routine 
and non- routine parameters for biomarker develop-
ment. Importantly, the daily systematic screening will 
help to identify patients with HLH at an early stage of 
the syndrome, which ultimately will improve patient 
care, safety and outcome. Moreover, describing a distinct 
pattern of biomarkers generates new hypothesis for 
future research, thereby potentially providing targets for 
therapy development. With regard to clinical practice, the 
HEMICU (Diagnostic biomarkers for adult haemophago-
cytic lymphohistiocytosis in critically ill patients) study 
seeks to inform clinicians about HLH and ICU therapies 
to improve outcomes for patients with HLH. However, it 
is of note that this study does not seek to advise the clini-
cian in charge to change therapy. No change in routine 
management is intended due to the observational study 
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design, and final decisions are left to the discretion of the 
responsible clinician.
Strengths and limitations
This study might be limited in that it only includes ICU 
patients and findings will not be generalisable to non- 
ICU patients. In addition, patients might have developed 
HLH before ICU admission and will thus be detected 
and measurements obtained at an advanced stage of the 
disease, possibly limiting comparability of the results. 
Moreover, we will not assess longitudinal parameters, 
preventing us from describing the dynamics of biomarkers 
over time. However, as this study aims to develop a tool 
facilitating diagnosis at the earliest possible time point, 
study endpoints will not be affected by lack of repeated 
measurements. Possible advances of this study include 
comprehensive laboratory testing of parameters which 
have previously been suggested to be associated with 
HLH.12–16 Previous studies, most of which are retrospec-
tive in nature, aimed at identifying associations to detect 
risk factors.2 22 Therefore, the HEMICU study is the first 
prospective study of its kind.
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